Clinical Trials Logo
  1. Home
  2. Asthma, Allergic
  3. NCT06027073

Biologics and Sublingual Immunotherapy — BSIPL  

Asthma, Allergic Clinical Trial

Official title:
Adding Biological Therapy to Asthmatic Patients on Allergen Immunotherapy to House Dust Mites

Clinical Trial Summary

Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.

Clinical Trial Description

Assess the effectiveness of combined therapy Actair® plus Xolair compared to monotherapy with Actair® or Xolair® or standard symptomatic therapy in patients with mild or moderate allergic asthma to HDM. Treatment duration: 24 months Follow-up duration:12 months Total duration: 36 months (not including screening and randomization period) May 2024 - March 2028 Consisting of a 4 to 5 months screening phase (with 1 month observation period prior to randomization) a treatment phase of 24 months and post-treatment follow-up phase 12 months ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06027073
Study type Interventional
Source Medical University of Silesia
Contact Andrzej Bozek, prof
Phone 0048608318547
Email andrzejbozek@o2.pl
Status Not yet recruiting
Phase Phase 4
Start date May 1, 2024
Completion date March 1, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Completed NCT03563521 - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed NCT02990117 - ICS Treatment Compliance of Asthma Patients
Completed NCT03468790 - Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. Phase 3
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT03455959 - Lung-Resident Memory Th2 Cells in Asthma N/A
Not yet recruiting NCT05352126 - Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma. N/A
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A
Recruiting NCT05720325 - Dupilumab Effects Against Aeroallergen Challenge Phase 2
Completed NCT03112577 - Study of REGN3500 and Dupilumab in Patients With Asthma Phase 1
Recruiting NCT04891237 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen Phase 3
Terminated NCT02953106 - Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis Phase 4
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT03705325 - Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer N/A
Recruiting NCT05478824 - IL13 Signaling in Allergic Asthma
Withdrawn NCT04035109 - Anakinra as a Rescue Treatment for Allergic Inflammation Phase 1/Phase 2
Suspended NCT04109807 - Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ) N/A
Recruiting NCT03983603 - Plant Stanol Esters and Preventing Asthma Symptoms N/A
Not yet recruiting NCT05740748 - Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma Phase 2